Ruxolitinib decreased the expression of cytokines and growth factors required for hematopoiesis by inhibiting JAK1/2- STAT pathways, which explains the improvement in PV-associated pruritis. This evidence concerns the gene SOAT1 and acquired polycythemia vera.